Pharmaceutical Composition of Nanotea Powder for the Prevention of Diabetic Nephropathy
DOI:
https://doi.org/10.61841/4m2pyb86Keywords:
Diabetic nephrotherapy (DN), diabetes mellitus, nanotea powder, lyophilization, streptozotocin (STZ), pathological damageAbstract
The chronic loss of kidney function in patients with long standing poorly controlled diabetes melitus and end-stage kidney failure globally is diabetic nephrotherapy (DN) which is also called "diabetic kidney disease." Numerous shifts in the processing units of the kidneys, i.e. the nephrons, accompany this. In chronic Type 1 and Type 2 diabetes mellitus, this type of disease is seen. Various research studies have been carried out in both fundamental science as well as clinical therapy which have increased the understanding and pathophysiology of diabetic nephrotherapy (DN) and expanded the therapeutic agents for the treatemnet. The present invention was designed to provide a novel nanotea powder formulation comprising of constituents that bear different mechanism of actions for the management of diabetic mellitus and diabetic nephropathy. Nanotea powder composed of Epigallocatechingallate, Rutin and Stevioside was formulated using lyophilization (freeze drying) method following which pharmaceutical characteristics of powder were evaluated. The disease was caused by a single dose of streptozotocin (STZ) (50mg / kg, i.p) in the overnight-fasted adult wistar rats weighing 180-210 g. After 8 weeks of STZ administration, diabetic nephropathy grew. Thereafter, Diabetic rats were treated with formulated nanotea powder by oral route for 15days. An array of biochemical estimations were performed such as serum glucose level, serum albumin, serum creatinine, blood urea nitrogen, serum total cholesterol, serum high density lipoprotein (HDL) and serum triglycerides, urine albumin and urine creatinine to measure the extent of pathological damage.
Downloads
References
[1] S. Thomas and J. Karalliedde, “Diabetic nephropathy,” Medicine (United Kingdom). 2019.
[2] International Diabetes Federation, IDF Diabetetes Atlas. 2017.
[3] International Diabetes Federation, “International Diabetes Federation. IDF Diabetes Atlas, 8th edition,”
2017.
[4] S. Hadjadj et al., “Different patterns of insulin resistance in relatives of type 1 diabetic patients with
retinopathy or nephropathy: The Genesis France-Belgium study,” Diabetes Care, 2004.
[5] J. Zhang, J. Liu, and X. Qin, “Advances in early biomarkers of diabetic nephropathy,” Revista da
Associacao Medica Brasileira. 2018.
[6] C. Magee, D. J. Grieve, C. J. Watson, and D. P. Brazil, “Diabetic Nephropathy: a Tangled Web to
Unweave,” Cardiovascular Drugs and Therapy. 2017.
[7] S. Kato et al., “Aspects of immune dysfunction in end-stage renal disease,” Clinical Journal of the
American Society of Nephrology. 2008.
[8] Y. N. Hall and G. M. Chertow, “End stage renal disease,” BMJ clinical evidence. 2007.
[9] M. A. hme. Abbasi, G. M. Chertow, and Y. N. Hall, “End-stage renal disease,” BMJ clinical evidence.
2010.
[10] R. J. Baker and C. J. Watson, “Renal transplantation,” Medicine (United Kingdom). 2019
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
